XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.
One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.
FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
This is the newest page. Registered accounts read further back.